The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II

Microcephalic Osteodysplastic Primordial Dwarfism Type II Clinical Trial

— NANPIM  

Official title:

The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPDII).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03139903
• Other study ID #: P081256
• Status: Completed
• Phase: N/A
• First received: March 23, 2017
• Last updated: November 17, 2017
• Start date: July 28, 2010
• Est. completion date: July 2015

Study information

• Verified date: November 2017
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study si to define morphological and epidemiological parameters and identify new symptoms in French patients with Seckel syndrome (SCKL) or microcephalic osteodysplastic primordial dwarfism type II (MOPDII).

Description:

Multicentre study, aiming to determine morphological and epidemiological parameters and identify new symptoms in French patients with SCKL or MOPDII.

At pre-inclusion visit: Realization of the photographs of: the face, entire body and the extremities (hands and feet) that will be serve for the collegiate decision of the inclusion or not of patients.

Patients are seen at inclusion V1 , a second visit V2 at 6-10 months after V1 and an annual follow-up visit.

At inclusion:

• Full Clinical Examination, specialized consultations (Otorhinolaryngology, stomatology, orthopedics, ophthalmology)

• Results of x-ray examinations and biological tests

• Assessment of the patients competencies and initiation of appropriate care ( orthophony and psychomotricity...)

• Assessment of intelligence and cognitive ability according the WISC-IV scale

• Blood testing for diagnosis and research.

Visit 2:

• Full Clinical Examination

• Cerebral angiography-MRI for all patients

• Programming a neurosurgery / neurovascular consultation based on MRI results

• Immuno-hematology and hepato-gastroenterology consultation if anomaly during the visit V1

Annual follow-up visit:

• Assessment of the complications of the disease and its clinical care

• Full clinical examination

• Skeletal x-ray and systematic orthopedic consultation

• Blood Check

• Prescription of tests if necessary depending to the complications identified of the disease

• Reevaluation of the care according to the detected symptoms

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 2015
• Est. primary completion date: July 16, 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Months and older

Eligibility

Inclusion Criteria:

Patients aged from 2 months to 50 years must present all of the following criteria:

• Symmetrical intrauterine growth restriction (IUGR) < - 2 DS, Birth size <-2 DS and Cranial perimeter of birth <-2 DS

• Postnatal growth restriction (size <-4DS)

• Microcephaly <-4DS

• Clinical Diagnosis of Seckel Syndrome or Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) by a geneticist

• Having given free and informed consent

Exclusion Criteria:

• Refutation of the diagnosis

• Parents' refusal to participate in genetic studies once the diagnosis of SCKL or MOPDII has been establish for the patient (major or minor)

• Allergy to gadolinium, contraindicating the realization of an Angio-MRI

• Absence of affiliation to a social security scheme or Universal Health Coverage.

Related Conditions & MeSH terms

• Dwarfism
• Dwarfism, Pituitary
• Facies
• Fetal Growth Retardation
• Microcephalic Osteodysplastic Primordial Dwarfism Type II
• Microcephaly
• Seckel Syndrome
• Syndrome

Locations

Country	Name	City	State
France	Medical Genetics Department and INSERM U781, Necker-Enfants Malades Hospital	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	to visualize any vascular abnormalities according the cerebral angiography-MRI		10 months
Secondary	Assessment of intelligence and cognitive ability according the Wechsler Intelligence Scale for Children (WISC-IV)		2 days
Secondary	Measurement of visual acuity		2 days